

## BioCLIA Autoimmune Reagent Kit, Cardiolipin IgG

(Chemiluminescent Microparticle Immunoassay)

Kit size	Cat. No.	GTIN Code
50 Tests/kit	MY00121	06924030402365
100 Tests/kit	MY00172	06924030402877

### INTENDED USE

The BioCLIA Autoimmune Reagent Kit, Cardiolipin IgG is intended for the *in vitro* semi-quantitative measurement of anti-Cardiolipin IgG antibodies in human serum and plasma as an aid in the diagnosis of primary Antiphospholipid Syndrome (APS) and those secondary to systemic lupus erythematosus (SLE) or SLE-like disorders in conjunction with other laboratory and clinical findings. It is an *in vitro* diagnostic medical device intended for laboratory professional use.

### SUMMARY AND EXPLANATION OF THE TEST

Antibodies against cardiolipin belong to the group of anti-phospholipid antibodies specific for negatively charged phospholipids, components of biological membranes.<sup>1, 2</sup> Anti-phospholipid antibodies are frequently found in sera of patients with systemic lupus erythematosus (SLE) and related diseases. These specific anti-cardiolipin antibodies recognize epitopes on a complex composed of cardiolipin and  $\beta$ 2-glycoprotein I which are only expressed when  $\beta$ 2-glycoprotein I interacts with cardiolipin<sup>4</sup>. The prevalence of anti-cardiolipin antibodies (aCL) in SLE is 50% and 5-40% in patients with systemic autoimmune disease like rheumatoid arthritis (RA), scleroderma, sjogren's syndrome or sharp syndrome.<sup>5, 6</sup>

The occurrence of anti-cardiolipin antibodies in patients with SLE and related diseases is typical of a secondary anti-phospholipid syndrome (APS). In contrast, anti-cardiolipin antibodies in patients with no other autoimmune diseases characterize the primary anti-phospholipid syndrome (APS). Many studies have shown a correlation between these autoantibodies and an enhanced incidence of thrombosis, thrombocytopenia and recurrent fetal loss. 80% of aCL positive patients develop venous or arterial thrombosis. Certain concentrations of Acl can be detected in heart or brain infarction patients, indicating an increased risk of other vascular complications where patients' conditions and prognosis have to be monitored. On spontaneous stillbirth, miscarriage or premature birth, aCL can be found positive even for women without any autoimmune disease symptoms.<sup>5, 6, 7</sup>

Many immunoglobulin isotypes against aCL can be found including aCL-IgA, aCL-IgG and aCL-IgM. Level of aCL-IgG is highly correlated with thrombocytopenia, thrombosis or abortion; aCL-IgM is relevant to haemolytic anaemia; while aCL-IgA seems less linked to autoimmune diseases<sup>8</sup>.

### PRINCIPLES OF THE PROCEDURE

BioCLIA Autoimmune Reagent Kit is a two-step immunoassay. The biotinylated antigen of interest is mixed with streptavidin coated

magnetic microparticles. Specific IgG in the patient's serum/plasma reacts with these to form a IgG-antigen complex. After incubation, a washing step removes the free and non-specifically bound molecules. Subsequently enzyme labeled anti-human IgG antibodies (conjugate) is added and this binds to the IgG-antigen complex. After further incubation, a second washing step removes the unbound conjugate. Then addition of substrate results in the emission of light and the relative light unit (RLU) intensity is measured. The relative light unit (RLU) intensity is proportional to the amount of antigen specific IgG present in the sample.

The BioCLIA Autoimmune Reagent Kit utilizes a predefined lot specific Master Curve which is uploaded into the instrument via the barcode provided in the kit. Based on the results of running two calibrators, the instrument specific Working Calibration Curve is generated and is used to calculate the concentration from the RLU obtained for each patient.

### WARNINGS AND PRECAUTIONS

- For professional *in vitro* diagnostic use only.
- Used on BioCLIA 6500 and BioCLIA 500 instruments only.
- Do not use reagents beyond the expiration dates.
- The kit contains human sourced materials. All recommended precautions for the handling of blood derivatives should be taken. Please refer to the existing laboratory safety regulations and good laboratory practice.
- Liquid waste and solid waste taken from BioCLIA 6500 and BioCLIA 500 should also be handled in accordance with the National or Local legislation.
- Once opened, the reagent cartridge must be stored in the instrument's reagent carousel. For the first placement of reagent into the instrument, please take care to avoid spilling the reagents.
- Spilled reagents should be cleaned up immediately. Comply with all National and local environmental regulations when disposing of wastes.

Improper cleaning or rinsing of the instrument may lead to chemical contamination of the reagents. Residues from common laboratory chemicals such as formalin, bleach, ethanol, or detergent can cause interference in the assay. Be sure to follow the recommended cleaning procedure as outlined in the BioCLIA 6500 and BioCLIA 500 User's Manual.



### Precautions

- The assay contains ProClin 300 0.0015%~0.6% as preservative and may cause an allergic skin reaction by skin contact. Avoid contact with skin. Wear protective gloves, protective clothing and protective glasses.
- The assay contains 5-Bromo-5-Nitro-1, 3-Dioxane (BND) < 1%

as preservative and may cause an allergic skin reaction by skin contact. Avoid contact with skin. Wear protective gloves, protective clothing and protective glasses.

- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Country in which the user and/or the patient is established.

#### MATERIALS SUPPLIED

- Antigen** Biotinylated antigen in PBS (pH 7.0-7.4).

ANTIGEN	BIOT
---------	------

Preservatives: 0.0015% < ProClin 300 < 0.6%.

- Conjugate** Alkaline phosphatase (AP) labeled anti-human IgG antibodies in 0.05 M MES (pH6.0).

CONJ	AP	G
------	----	---

Preservatives: 0.0015% < ProClin 300 < 0.6%.

- Microparticle** Streptavidin coated microparticles in 0.01M PBS (pH 7.4).

M	STREP
---	-------

Preservatives: 5-Bromo-5-Nitro-1, 3-Dioxane (BND) < 1%.

Components	50 Tests/Kit	100 Tests/Kit
Antigen	1 x 2.5 mL	1 x 5 mL
Conjugate	1 x 6.75 mL	1 x 13.5 mL
Microparticle	1 x 2.5mL	1 x 5 mL

#### ADDITIONAL MATERIALS SUPPLIED SEPARATELY

Product	CATALOGUE No.
BioCLIA Autoimmune Calibrator Set, Cardiolipin IgG	MY00223 (2 x 1 mL) MY00274 (4 x 1 mL)
BioCLIA Autoimmune Control Set, Cardiolipin IgG	MY00325 (2 x 1 mL) MY00376 (4 x 1 mL)
BioCLIA Sample Diluent I	MY00965
BioCLIA System Wash Buffer	MY00404
BioCLIA System Substrate	MY00405
BioCLIA 6500	MA00243
BioCLIA 500	MA00502
BioCLIA Cuvettes	MA00244 (2000 pcs/bag) MA00549 (65 pcs/box)
BioCLIA Silicone gasket (Small)	MV00195
BioCLIA Silicone gasket (Large)	MV00196

#### MATERIALS REQUIRED

- Distilled or deionized Water

#### STORAGE AND STABILITY

- Store the kit at 2-8 °C.
- The shelf life of the unopened kit is 12 months.
- Opened reagents or onboard reagents may be used for 28 successive days. The software of the BioCLIA instruments monitors the onboard (in-use) expiration of the reagent cartridge. The system will not allow use of a reagent which has expired.

#### SPECIMEN COLLECTION, STORAGE AND HANDLING

- Serum from venous can be used.
- Collect blood specimens using standard procedures.
- Test serum should be clear and free from hemolysis.
- Cloudy samples should be clarified by centrifugation at 5000 rpm for 5 minutes before use. For samples with the presence of fibrin, ensure that complete clot formation has taken place prior to centrifugation of samples. Some samples, particularly those from patients receiving anticoagulant therapy, may require increased clotting time.
- Specimens may be refrigerated at 2-8 °C for up to seven days or stored at -20°C up to six months.
- Specimens may be kept onboard on BioCLIA instruments under room temperature (18-25°C) for up to 2 hours.
- Avoid repeated freezing and thawing.

#### ASSAY PROCEDURE

Detailed information about operating the BioCLIA instruments can be taken from the Instrument User's Manual.

Note that, it is important to perform all routine maintenance procedures for optimal performance.

#### Sample Dilution

The specimens are diluted with BioCLIA Sample Diluent I before testing (dilution ratio 1:19) by the BioCLIA instruments automatically.

#### Assay Calibration

The BioCLIA Autoimmune Reagent Kit utilizes a predefined lot specific Master Curve which is uploaded into the instrument via the barcode provided in the kit. Based on the results of running two calibrators, the instrument specific Working Calibration Curve is generated and is used to calculate the concentration from the RLU obtained for each patient.

For each new lot of reagents, please calibrate prior to the first time use, and every 28 days thereafter. The software will not allow the lot to be used if the above requirements are not met.

#### Control

The control procedure should be done before running the specimens each day. Users also can adjust the control procedure

period according to their own lab frequency.  
Each Laboratory should establish its own reference ranges.

### **Programming and Running samples**

1. Put the kit into any empty position of the reagent chamber of the BioCLIA instruments. Details of the kit can be uploaded into the instrument system through the scanning of reagent barcode, and can also be set manually.
2. The information of calibrator / quality control is identified by scanning the calibrator / control barcodes, and the position of calibrator / quality control is assigned in the instrument system.
3. The sample to be tested is placed on the instrument sample rack chamber, and the corresponding test information is edited through the instrument supporting software.
4. Start the operation procedure, and all calibrator / quality control / sample processing steps will be automatically executed.

### **CALCULATION OF RESULTS**

Calculation and interpretation of results will be performed automatically by software on BioCLIA instruments.

### **RESULT INTERPRETATION**

Specimens with concentration <20 RU/mL, should be interpreted as negative;

Specimens with concentration  $\geq 20$  RU/mL, should be interpreted as positive.

The test results only reflect the amount of antigen specific IgG present in the sample and should be diagnosed in conjunction with other laboratory and clinical findings.

### **CUT-OFF VALUE DETERMINATION**

120 clinical samples, including 30 positive sera, 30 negative sera, 30 positive plasmas and 30 negative plasmas were collected and evaluated. Results were analyzed using the receiver-operating characteristic curve (ROC) and the cut-off value was determined at 20 RU/mL.

### **PERFORMANCE CHARACTERISTICS**

#### **ACCURACY / SPIKED RECOVERY**

The accuracy/spiked recovery was determined by analyzing samples spiked with known amounts of antibody into sample matrix. Specific antibody positive samples (low 100 RU/mL, mid 200 RU/mL, high 300RU/mL) were spiked into two matrixes (50 and 100 RU/mL) separately at the volume ratio of 1:9, making totally 6 spiked samples and each sample was tested in triplicate. The spiked recovery for the concentration of autoantibodies to specific antigen was calculated. \*

Spiked Conc.	Matrix 50 RU/mL			Matrix 100 RU/mL		
	Obs	Exp.	Obs/Exp	Obs	Exp.	Obs/Exp
Neat	49.37			96.56		

100 RU/mL	55.05	54.4	101.1%	102.20	96.9	105.5%
200 RU/mL	66.40	64.4	103.1%	109.63	106.9	102.6%
300 RU/mL	74.88	74.4	100.6%	118.39	116.9	101.3%

\*Representative data; results in individual laboratories may vary from these data.

### **TRACEABILITY**

This assay system is calibrated in relative arbitrary units since no international reference preparation is available for this assay. The reported values were determined with multiple runs on the BioCLIA 6500 and BioCLIA 500 using specific reagents against an in-house standard.

### **PRECISION**

A study based on guidance from (NCCLS) document EP-A<sup>18</sup> was performed.

**Intra-assay precision:** Four samples (negative, low, moderate, and high) were taken and tested with 10 replicates for each in a single run. Coefficient of variation (CV) was calculated for each of four samples. The results for intra-assay precision are shown in the table below.

**Inter-assay precision:** Four samples (negative, low, moderate, and high) were taken and tested with 4 replicates in a single run, two runs per day for 10 days. Coefficient of variation (CV) was calculated for each of four samples. The results for inter-assay precision are shown in the table below. \*

Intra-assay precision: CV < 10%				
Intra-Assay	Sample1	Sample2	Sample3	Sample4
Mean(RU/mL)	10.17	19.58	102.42	348.68
CV	6.93%	4.45%	4.80%	6.31%

Inter-assay precision: CV < 15%				
Inter-Assay	Sample1	Sample2	Sample3	Sample4
Mean(RU/mL)	10.05	19.68	99.77	345.69
CV	7.92%	5.95%	8.14%	6.05%

\*Representative data; results in individual laboratories may vary from these data.

### **LIMIT OF BLANK / DETECTION (LOB/LOD)**

LOB/LOD was determined according to CLSI EP17-A guideline.

The assay is designed to have LoB/LoD of  $\leq 0.5$  RU/mL.

### **LINEARITY**

The linear range of the assay is 2-400 RU/mL.

The linear range was determined by serially diluting a sample containing high levels of antigen specific IgG with a negative sample and covering the entire assay linear range according to the scheme in CLSI EP6-A. The expected value was plotted against the observed value, and linear regression analysis was performed to get slope, intercept and coefficient of correlation (r) values. The results are summarized in the table below\*:

Slope	Intercept	r
1.01	+0.10	0.99

\*Representative data; results in individual laboratories may vary from these data.

### INTERFERENCE

No interference has been observed with bilirubin, hemoglobin, triglycerides, rheumatoid factor (RF), human anti-mouse antibody (HAMA) at the levels indicated below.

- Bilirubin  $\leq$  40 mg/dL;
- Hemoglobin  $\leq$  150 mg/dL;
- Triglycerides  $\leq$  1,000 mg/dL;
- Rheumatoid factor (RF)  $\leq$  1,000 IU/mL;
- Human anti-mouse antibody (HAMA)  $\leq$  2,000 ng/mL.

### METHOD COMPARISON

Method comparison was implemented by comparing clinical sample results of the assay to the results of predicated assay. The results are shown in the table below.

Clinical Sample		BioCLIA Autoimmune Reagent Kit, Cardiolipin IgG		
		-	+	Total
Predicated Method	-	57	3	60
	+	5	35	40
	Total	62	38	100

<b>Sensitivity</b>	87.5%
<b>Specificity</b>	95.0%
<b>Total agreement</b>	92.0%

### LIMITATIONS

- The effectiveness of this kit is only confirmed for human serum/plasma, the applicability of the other kinds of samples is not verified.
- Reliable and reproducible results will be obtained when the assay procedure is carried out in accordance with the instructions and with adherence to good laboratory practice.
- Clinical diagnosis should not be made on the findings of a single test result, but should be interpreted with all clinical and laboratory findings.

### SYMBOLS

	Catalog Number		Use-by date
	In Vitro diagnostic medical device		Lot Number
	Store between +2°C and +8°C		Consult Instruction for Use
	Manufacturer		Authorized Representative in the European Community
	CE Marking		Contains Sufficient for <n> Tests
	Biological Risk		GHS07 Warning

	Biotinylated antigen
	AP labeled anti-human IgG antibody
	Streptavidin coated microparticles

### REFERENCES

1. SCHLAME M, BRODY S, HOSTETLER KY. Mitochondrial cardiolipin in diverse eukaryotes. *European Journal of Biochemistry* 1993;212:727-33.
2. Houtkooper R, Vaz F. Cardiolipin, the heart of mitochondrial metabolism. *Cellular and Molecular Life Sciences* 2008;65:2493-506.
3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). *Proceedings of the National Academy of Sciences* 1990;87:4120-24.
4. Schlame M, Horvath L, Vigh L. Relationship between lipid saturation and lipid-protein interaction in liver mitochondria modified by catalytic hydrogenation with reference to cardiolipin molecular species. *Biochemical Journal* 1990;265:79-85.
5. Spinella A, Lumetti F, Sandri G, Cestelli V, Mascia MT. Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder. *Case reports in infectious diseases* 2012;2012.
6. Hokama Y, Campora CE, Hara C, Kuribayashi T, Le Huynh D, Yabusaki K. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. *Journal of clinical laboratory analysis* 2009;23:210-12.
7. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. *Annals of the New York Academy of Sciences* 2003;991:120-31.
8. Pangborn MC. Isolation and purification of a serologically active phospholipid from beef heart. *Journal of biological chemistry* 1942;143:247-56.
9. US Department of Labor, Occupational Safety and Health Administration, 29 CFR Part 1910.1030, Occupational Exposure to Bloodborne Pathogens. Jan 2001.
10. US Department of Health and Human Services. Biosafety in Microbiological and Biomedical Laboratories, Fourth Edition. Washington, DC: US Government Printing Office, May 1999.
11. World Health Organization. Laboratory Biosafety Manual. Geneva: World Health Organization. 2004.
12. Clinical and Laboratory Standards Institute. Protection of Laboratory Workers from Occupationally Acquired Infections: Approved Guideline - Third Edition. CLSI Document M29-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.



**HOB Biotech Group Corp., Ltd.**  
C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park,  
Suzhou, Jiangsu, 215123, China

### CONTACT INFORMATION:

TEL (+86)512-69561996

Fax (+86)512-62956652

WEBSITE: : [www.hob-biotech.com](http://www.hob-biotech.com)

CUSTOMER SERVICE: TEL (+86)4008601202



**EUROPE REPRESENTATIVE:** Emergo Europe

**ADDRESS/LOCATION:**

Prinsessegracht 20, 2514 AP The Hague, The Netherlands

**The eIFU is available on Website:**

<http://en.hob-biotech.com/usercenter/login.aspx>

**TECHNICAL ASSISTANCE**

For technical assistance, contact your National Distributor.

Date of issue: 17<sup>th</sup> March 2019

Date of revision: 20<sup>th</sup> December 2021

Change Control Number: CN21129E

Version: A/1 (EN)